1Gupta AK, Chwetzoff E, Del Rosso J, et al.Hepatic safety of itraconazole. J Cutan Med Surg, 2002, 6: 210-213.
2Gupta AK, Shear NH. Safety review of the oral antifungal agents used to treat superficial mycoses. Int J Dermatol, 1999, 38Suppl 2: 40-52.
3Hall M, Monka C, Krupp P, et al. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol, 1997, 133: 1213-1219.
4Hall AP, Tate B. Acute generalized exanthematous pustulosis associated with oral terbinafine. Australas J Dermatol, 2000, 41:42-45.
5Callen JP, Hughes AP, Kulp-Shorten C. et al. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol, 2001, 137:1196-1198.
6Stricker BH, Van Riemsdijk MM, Sturkenboom MC, et al. Taste loss to terbinafine: a case-control study of potential risk factors.Br J Clin Pharmacol, 1996, 42: 313-318.
7Shapiro M, Li LJ, Miller J. Terbinafine-induced neutropenia. Br J Dermatol, 1999,140: 1196-1997.
8Tsai HH, Lee WR, Hu CH. Isolated thrombocytopenia associated with oral terbinafine.Br J Dennatol, 2002, 147: 627-628.
9Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf,2000, 22: 33-52.
10Rodgers P, Bassler M. Treating onychomycosis. Am Fam Physician, 2001, 63: 663-672, 677-678.
